Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
Summit Therapeutics
733 posts
Summit Therapeutics
@SMMT_TX
Official account for news & info on Summit Therapeutics, Inc., a biotech targeting significant, unmet medical needs, focused on oncology.
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
- Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody bit.ly/3uuwMxQ
- Summit announces ezutromid significantly reduced muscle inflammation in Phase 2 trial in DMD: inpublic.globenewswire.com/releaseDetails…
- Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD: inpublic.globenewswire.com/releaseDetails…
- Summit Therapeutics Raises $235 Million Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement $235 Million in Net Proceeds Raised at Sept 11 2024 Closing Price of $22.70
- Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLC Topline data from the HARMONi Trial Is Expected in Mid-2025 businesswire.com/news/home/2024…
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
- .@DPPSpain's conference is off to a great start in Madrid! Thank you for inviting us to share our work with the families in Spain!
- H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development @JackWestMD Brings over 25 Years of Trusted Clinical Expertise in Thoracic Oncology businesswire.com/news/home/2023…
- Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority bit.ly/3opffTS
- Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- We've been awarded a grant from BARDA worth up to $62M to support development of ridinilazole in #cdiff otp.investis.com/clients/uk/sum…
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
